GRA VentureLab company helping to develop promising cancer vaccine

December 14, 2011 at 3:15 pm Leave a comment

GRA VentureLab company Viamune will help to develop and commercialize a promising new cancer vaccine and the technologies used to create it.  Based on the work of researchers at the University of Georgia and the Mayo Clinic, the vaccine dramatically reduces tumors in a mouse model that mimics 90 percent of human breast and pancreatic cancer cases, including those resistant to common treatments.  According to the researchers, the vaccine elicits a very strong immune response, activating all three components of the immune system to reduce tumor size by an average of 80 percent. 

If all goes well, the researchers hope to begin to test the safety of the vaccine in humans in late 2013.  Read more>

Entry filed under: Commercialization/VentureLab, News. Tags: .

GRA Eminent Scholar Steve Dalton and colleagues break new ground in stem cell applications GRA Eminent Scholar Voit honored

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Categories

Feeds


Follow

Get every new post delivered to your Inbox.